Tosymra is owned by Upsher Smith Labs.
Tosymra contains Sumatriptan.
Tosymra has a total of 8 drug patents out of which 0 drug patents have expired.
Tosymra was authorised for market use on 25 January, 2019.
Tosymra is available in spray;nasal dosage forms.
Tosymra can be used as acute treatment of migraine.
The generics of Tosymra are possible to be released after 19 July, 2031.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9283280 | UPSHER SMITH LABS | Compositions for drug administration |
May, 2026
(3 years from now) | |
US8268791 | UPSHER SMITH LABS | Alkylglycoside compositions for drug administration |
May, 2026
(3 years from now) | |
US8440631 | UPSHER SMITH LABS | Compositions for drug administration |
May, 2026
(3 years from now) | |
US11337962 | UPSHER SMITH LABS | Formulations comprising triptan compounds |
Jun, 2030
(7 years from now) | |
US9974770 | UPSHER SMITH LABS | Formulations comprising triptan compounds |
Jun, 2030
(7 years from now) | |
US9610280 | UPSHER SMITH LABS | Formulations comprising triptan compounds |
Jun, 2030
(7 years from now) | |
US10603305 | UPSHER SMITH LABS | Formulations comprising triptan compounds |
Jun, 2030
(7 years from now) | |
US9211282 | UPSHER SMITH LABS | Formulations comprising triptan compounds |
Jul, 2031
(8 years from now) |
Drugs and Companies using SUMATRIPTAN ingredient
Market Authorisation Date: 25 January, 2019
Treatment: Acute treatment of migraine
Dosage: SPRAY;NASAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic